Biotech | April 13, 2022
Novel Covid-19 vaccine may protect the immunocompromised
The peptide-based vaccine induces a t cell-dependent response
The peptide-based vaccine induces a t cell-dependent response
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
Pharmapack trends are a key barometer of global device and packing opportunities in 2022
GRC 54276 has shown tumour cell killing ability in preclinical studies as a single agent and as well in combination with checkpoint inhibitors, making it a high-priority target in immuno-oncology
Lilly may be eligible for up to US $ 225m in payments based upon the achievement of pre-specified development, regulatory and commercial milestones
Further demonstrates Honeywell's commitment to greenhouse gas reduction and support of customers' sustainability goals through innovative new products
Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
Subscribe To Our Newsletter & Stay Updated
